Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View ZVRA insider activity ↗

ZVRAZEVRA THERAPEUTICS, INC.

THE LATEST REPORTED YEAR

The company reported a profit.

$83.23M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$106.47MYear ended December 31, 2025
Profit or loss$83.23MYear ended December 31, 2025
Cash from the business-$1.6MYear ended December 31, 2025
Total assets$302.71MAs of June 30, 2026
Total liabilities$85.06MAs of June 30, 2026
Cash & equivalents$145.32MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$0
2018-12
$12.84M
2019-12
$13.29M
2020-12
$28.65M
2021-12
$10.16M
2022-12
$27.46M
2023-12
$23.61M
2024-12
$106.47M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$106,470,000March 9, 202610-K ↗
January 1, 2024 – December 31, 2024$23,612,000March 9, 202610-K ↗
January 1, 2023 – December 31, 2023$27,461,000March 12, 202510-K ↗
January 1, 2022 – December 31, 2022$10,161,000April 1, 202410-K ↗
January 1, 2021 – December 31, 2021$28,650,000March 7, 202310-K ↗
January 1, 2020 – December 31, 2020$13,288,000March 31, 202210-K ↗
January 1, 2019 – December 31, 2019$12,839,000March 12, 202110-K ↗
January 1, 2018 – December 31, 2018$0February 28, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · Retrieved October 12, 2026

Response SHA-256: e6444155e299482d8e745cbcf52e94d14227a2668e6d953fd1eb25cffef79d18

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.